Ankara University Department of Medical Oncology, Ankara, Turkey
Ankara University Department of Medical Oncology, Ankara, Turkey.
In Vivo. 2024 Nov-Dec;38(6):2921-2927. doi: 10.21873/invivo.13774.
BACKGROUND/AIM: Regorafenib is an oral multikinase inhibitor used in later lines for metastatic colorectal carcinoma (mCRC) treatment, but its efficacy and tolerability are low. To improve the response rates and ameliorate adverse effects, different strategies have been implemented. In our study, we examined the effect of statin usage in patients with mCRC treated with regorafenib.
This single-center retrospective study included patients with mCRC who were treated with regorafenib between January 2015 and December 2023. The primary outcomes were progression-free survival (PFS) and overall survival (OS), and the secondary outcomes were adverse effects and the tolerability of regorafenib.
The data of 105 patients were collected retrospectively. The median age of the patients was 66 years, and 60 patients were male. Seventeen patients (16.1%) were receiving statins. Statin-using patients were significantly older than non-users (72 years vs. 66.5 years, p=0.05). Comorbid diseases were more common in patients using statins. The median PFS was 1.9 months for statin users and 4.2 months for statin non-users (p<0.001), and the median OS was 4.7 vs. 6.7 months (p=0.01). Cox regression revealed that statin usage was significantly associated with a higher hazard ratio (HR) for PFS (2.53) and OS (2.06) (both p<0.01 and p=0.02, respectively).
Statins are associated with decreased survival and response rates in patients with mCRC treated with regorafenib. However, further studies are needed to confirm these results.
背景/目的：regorafenib 是一种口服多激酶抑制剂，用于转移性结直肠癌（mCRC）的后线治疗，但疗效和耐受性较低。为了提高缓解率并改善不良反应，已实施了不同的策略。在我们的研究中，我们研究了 mCRC 患者在接受regorafenib 治疗时使用他汀类药物的效果。
这项单中心回顾性研究纳入了 2015 年 1 月至 2023 年 12 月期间接受 regorafenib 治疗的 mCRC 患者。主要结局是无进展生存期（PFS）和总生存期（OS），次要结局是不良反应和 regorafenib 的耐受性。
回顾性收集了 105 例患者的数据。患者的中位年龄为 66 岁，60 例为男性。17 例（16.1%）正在服用他汀类药物。使用他汀类药物的患者明显比未使用者年龄更大（72 岁比 66.5 岁，p=0.05）。使用他汀类药物的患者合并症更常见。他汀类药物使用者的中位 PFS 为 1.9 个月，而未使用者为 4.2 个月（p<0.001），中位 OS 分别为 4.7 个月和 6.7 个月（p=0.01）。Cox 回归显示，他汀类药物的使用与 PFS（2.53）和 OS（2.06）的更高风险比（HR）显著相关（均 p<0.01 和 p=0.02）。
他汀类药物与 mCRC 患者接受 regorafenib 治疗后的生存和缓解率降低相关。然而，需要进一步的研究来证实这些结果。
